medEctoin®

- **medEctoin**[®] is a clinically studied and proven, very tolerable substance for the use in Pharmaceutical Industry, Healthcare Products and as substance in Medical Devices (OTC).
- It is a cyclic amino acid derivate with highly effective inflammation-reducing and membranestabilizing properties. The efficacy of **medEctoin**[®] has been proven in various clinical trials.
- medEctoin[®] is the only "Made in Germany" and 100% natural ectoine in the market qualified for the use in Pharmaceuticals, Healthcare products and as substance to use in Medical Devices (OTC)

Trade name	medEctoin®		
INCI name	Ectoin		
Chemical name	(4S)-2-methyl-1,4,5,6-tetra-hydropyrimidine-4-carboxylic acid		
CAS No.	96702-03-3		
EINECS / EC No.	431-910-1		
REACH No.	01-0000017811-72-0001		
Description	Cyclic amino acid derivate		
Structure			
Level of use	0.5% - no upper limit		
Product of use	Pharmaceuticals, Healthcare Products, Medical Devices (OTC)		
Certifications	NATRUE, COSMOS, EcoCert		
Application media	Water phase		
Stability	pH 1-9, very high temperatures (>85°C), sub-zero temperatures (e.g. freeze-drying); light stable, stable against oxygen		
Solubility	Excellent solubility in water (~ 550 g/l); glycerin		
Shelf life	> 5 years		
Preservation	Preservative free		
Origin	Manufactured by a biotechnological manufacturing process (fermentation) according to EN ISO 13485 at the bitop AG plant in Dortmund, Germany.		
Pack units	1kg (wide-mouth PE bottle) , 5kg, 10kg (PE bag in cardboard packaging), 25kg (PE bag in hobbock on euro palette)		










Studies conducted with medEctoin[®] in Healthcare Products (OTC)

Indication	Studies	Patients	Main Outcome
Allergy	<10	<650	Improvement of local symptoms of eye & noseAs effective as standard drugs
Airway Diseases	3	189	 Reduction of specific inflammation markers (Asthma/ COPD) Improvement of hyperreagibility Reduction of Bronchitis symptoms
Cough & Cold	6	350 (nasal)	 Nose: reduction of rhinitis & rhinosinusitis, very good sensoric properties Throat: significant reduction of lymph node swelling
Dry Eyes Dry Nose	<10	>1.000 (eye)	 Eyes: significant improvement of TBUT, non inferior to HA eye drops, improvement of wound healing, reduction of non specific inflammation Nose: improvement of combined dry nose symptoms score
Dermatology	>15	6 with MD >9 with Cosmetics	 Reduction of of local Atopic Dermatitis symptoms, erythema, TEWL, irritation score, dryness, scaling (N>500) Reduction of local Psoriasis symptoms (N>90) Anti Aging / stress protection efficacy (N>400)
Supportive Care	1	3 case series >60 patients	 Reduction of oncology treatment reduced inflammatory response Prophylactic and therapeutic reduction of mucositis symptoms
Gynecology and Women's Health	1	>200	 Long term hydration and regeneration of vaginal mucosa Superior treatment of Vaginal atrophy and vaginal dryness compared to Hyaluronic Acid







www.bitop.de

Made in Germany